Home   >  

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
TAK-418 Chemical Structure
BCP44939 TAK-418 1818252-53-7
TAK-418 is a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1A (LSD1).
KDM2A/7A-IN-1 Chemical Structure
BCP44938 KDM2A/7A-IN-1 2169272-46-0
KDM2A/7A-IN-1 is a first-in-class, selective and cell-permeable inhibitor of histone lysine demethylases KDM2A/7A, with an IC50 of 0.16 μM for KDM2A, exhibits 75 fold selevtivity over other JmjC lysine demethylases, and is inactive on methyl transferases, and histone acetyl transferases.
SGC3027 Chemical Structure
BCP44921 SGC3027 2624313-13-7
SGC3027 is a histone methyltransferase inhibitor.
CYD19 Chemical Structure
BCP44927 CYD19 CYD19
CYD19 is a novel potent CBP/p300-Snail interaction inhibitor, suppressing tumor growth and metastasis in wild-type p53-expressing cancer, forming a high-affinity interaction with the evolutionarily conserved arginine-174 pocket of Snail protein, reversing Snail-mediated epithelial-mesenchymal transition (EMT) and impairs EMT-associated tumor invasion and metastasis.
MRTX-1719 Chemical Structure
BCP44551 MRTX-1719 2630904-45-7
MRTX1719 is a first-in-class MTA-cooperative PRMT5 inhibitor that selectively elicits antitumor activity in MTAP/CDKN2A deleted cancer models
IM156 Chemical Structure
BCP44337 IM156 1422365-94-3
IM156, a chemical derivative of metformin, is a potent AMPK activator that increases AMPK phosphorylation. IM156 attenuates aging-associated cognitive impairment in animal model.
Quisinostat HCl Chemical Structure
BCP44306 Quisinostat HCl 1083078-98-1
Quisinostat, also known as JNJ-26481585, is an orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.
Bomedemstat ditosylate Chemical Structure
BCP44102 Bomedemstat ditosylate 1990504-72-7
Bomedemstat is a lysine-specific histone demethylase 1 (LSD1) inhibitor with antineoplastic activity.
Pulrodemstat Chemical Structure
BCP44101 Pulrodemstat 1821307-10-1
Pulrodemstat is a potent and orally active LSD1 inhibitor. CC-90011 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively. CC-90011 exhibits potent on-target induction of cellular differentiation in acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cell lines, and antitumor efficacy in patient-derived xenograft (PDX) SCLC models.
Ilginatinib Chemical Structure
BCP44119 Ilginatinib 1239358-86-1
Ilginatinib is an orally bioavailable, small molecule inhibitor of Janus-associated kinase 2 (JAK2) and Src-family kinases, with potential antineoplastic activity. JAK2/Src inhibitor NS-018 competes with ATP for binding to JAK2 as well as the mutated form JAK2V617F, thereby inhibiting the activation of JAK2 and downstream molecules in the JAK2/STAT3 (signal transducer and activator of transcription 3) signaling pathway that plays an important role in normal development, particularly hematopoiesis. In addition, NS-018 inhibits the Src family tyrosine kinases. This eventually leads to the induction of tumor cell apoptosis.
123下一页末页共 623 条记录 1 / 63 页